PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.03
Negative P/E indicates losses - a classic Benjamin Graham warning sign. While possibly indicating turnaround potential, verify Debt-to-Equity and Current Ratio for financial stability.
4088.78
P/S above 5.0 - Speculative zone. Seth Klarman would demand extraordinary evidence of future profitability. Examine all growth and margin metrics.
2.58
P/B 2.0-3.0 - Premium territory. Seth Klarman would demand clear evidence of understated assets or superior economics.
-31.79
Negative P/FCF indicates negative free cash flow - a classic Benjamin Graham warning sign. Verify Working Capital management and Capital Expenditure patterns.
-32.20
Negative P/OCF indicates negative operating cash flow - a classic Benjamin Graham warning sign. Verify Working Capital management and Revenue Collection efficiency.
2.58
Price above 140% of fair value - Danger zone. Philip Fisher would require extraordinary growth evidence. Scrutinize all valuation inputs carefully.
-4.97%
Negative earnings yield indicates losses - a classic Benjamin Graham warning sign. Verify Operating Cash Flow and examine path to profitability.
-3.15%
Negative FCF yield indicates negative free cash flow - a classic Benjamin Graham warning sign. Verify Capital Expenditure patterns and Working Capital management.